Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 25Neoplasms 19Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Pain 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lymphoma, Follicular 6Leukemia 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Non-Muscle Invasive Bladder Neoplasms 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leiomyoma 4Carcinoma 4Urologic Neoplasms 3Urogenital Neoplasms 3Papillomavirus Infections 3

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Kidney Failure, Chronic × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡